AzTrials
AzTrials

Increase in Urobilinogen in Urine Prior to DeliveryNCT00826605

Urobilinogen, Maternal Weight Loss and Impending Parturition at Term

An observational study of Increase in Urobilinogen in Urine Prior to Delivery and Weight Loss After 37 Weeks Gestation Prior to Delivery, run by Oklahoma State University Center for Health Sciences at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study, then, is to search existing clinic and hospital records for answers to the following two questions: (1) Do pregnant women who are at least 37 weeks gestation and who have an increase in urubilinogen on urine dipstick at a prenatal appointment have a statistically significant shorter average… Read more about this study

Who is it for?
Ages 18 to 34 years, women onlyHealthy volunteers can take part
How many people
200 participants
Where
2 sitesUnited States
Study dates
Jan 2009to Oct 2009
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 34 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Study population: Population is mothers between the ages of 18 and 34 years of age with a single intrauterine pregnancy between 37 weeks and 41 weeks gestational age. (Both very young mothers and women 35 and older have increased risk of premature delivery.) The patients will have an admission diagnosis of either active labor or spontaneous rupture of membranes. Active labor is defined as uterine contractions resulting in changes either in the cervical dilatation, the effacement of the cervix and/or descent of the fetal head in the pelvis.

Inclusion Criteria: Our study population will consist of women between the ages of 18 and 34 who delivered a single, viable, term infant at OSU Medical Center between January 1, 2002 and December 31, 2006. Gestational age must be greater than 37 weeks and less than 41 weeks, as ascertained by certain last menstrual period and/or first trimester ultrasound. The chart must include a diagnosis of active labor or spontaneous rupture of membranes, and the patient must have had at least two third-trimester prenatal checkups at OSU Houston Center OB/GYN, including one during the last two weeks of gestation. We will define a term infant as 37 weeks gestation or greater (3). Our study population will consist of mainly Medicaid patients. The ethnic blend of our study population will include Caucasian, African-American, Hispanic, American Indian, and Asian women.

-

Exclusion Criteria: We will exclude women with multiple gestation, because they are at risk of preterm labor. We will also exclude anyone else who had preterm delivery. In addition, we will exclude women with a diagnosis of liver disease, including intrahepatic cholestasis and hepatitis, chronic hypertension, intraamniotic infection, preeclampsia or its variant, HELLP syndrome, cholelithiasis, inadequate prenatal care, preterm labor, or induction of labor (other than due to premature rupture of membranes).

-

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • OSU Houston Center OB/Gyn Clinic

    Tulsa, Oklahoma, 74127

  • OSU Medical Center

    Tulsa, Oklahoma, 74127

Other trials in United States

About this study

Official title: Retrospective Investigation of Presence of Urobilinogen and Maternal Weight Loss as Indications of Impending Parturition in the Term Gravida

The purpose of this study, then, is to search existing clinic and hospital records for answers to the following two questions: (1) Do pregnant women who are at least 37 weeks gestation and who have an increase in urubilinogen on urine dipstick at a prenatal appointment have a statistically significant shorter average time before going into active labor than their negative counterparts? (2) Do pregnant women who are at least 37 weeks gestation and who show a modest weight loss between two prenatal appointments have a statistically significant shorter average time before going into active labor than their counterparts who did not lose weight?

Read the detailed description

Rationale/Background:

This study is a retrospective review of records which examines the possibility of two markers for the onset of active labor (contractions which result in a change in the uterine cervical dilatation) on routine clinical prenatal assessment. The markers in question are an elevation of urobilinogen on routine dipstick and slight maternal weight loss. An apparent clinical correlation between the presence of urobilinogen, maternal weight loss and onset of active labor has been observed in our patient population. Our hypothesis is that these markers in the term gravida are an indication of delivery within a week of their appearance on routine prenatal evaluation. Should a correlation exist, the clinician would have a relatively inexpensive way of identifying patients that could deliver within the week and could possibly predict those patients that would have success with induction, as the normal labor process may have begun. The purpose of this study, then, is to search existing clinic and hospital records for answers to the following two questions: (1) Do pregnant women who are at least 37 weeks gestation and who have an increase in urobilinogen on urine dipstick at a prenatal appointment have a statistically significant shorter average time before going into active labor than their negative counterparts? (2) Do pregnant women who are at least 37 weeks gestation and who show a modest weight loss between two prenatal appointments have a statistically significant shorter average time before going into active labor than their counterparts who did not lose weight? In humans, the signals that initiate labor are not completely understood. While many theories have been explored, an exact pathway has not yet been determined. Urobilinogen is formed from conversion of conjugated bilirubin in the intestine by bacteria. A fraction of the urobiliogen is then reabsorbed into the bloodstream and filtered by the kidneys, becoming a colorless component of urine. Normally, only 1-4 mg of urobilinogen is excreted in the urine per day. Hemolytic processes, hepatocellular damage, and cholestasis can elevate urobilinogen in the urine. Routine dipstick tests have a normal urobilinogen range of 0.2 to 1 mg/dl (1). In this study, we will examine the urine dipsticks for an increased change in the urobilinogen levels within the last two prenatal appointments prior to delivery.

No previous studies could be located regarding a link between an elevation in urobilinogen and/or minor maternal weight loss and parturition, labor, onset. There have been studies to suggest rationale for our clinical observation, however. Estrogens and progesterone both play a role in the growth and contractility of uterine myometrial cells. Progesterone tends to promote uterine relaxation, hence the name "pro-gest…". In most species, progesterone levels dramatically fall, a 'withdrawal', prior to the onset of labor. However, in human and higher level primates, the progesterone and estrogen levels are both elevated in later gestation and during parturition. The "withdrawal" in humans, therefore, may be mediated by changes in the myometrial responsiveness to progesterone (2).

Estrogens induce myometrial contractility. Estriol is the most abundant estrogen during pregnancy and is produced by the placenta. It first appears at approximately the ninth week of gestation from the last menstrual period (3). Plasma concentrations of this estrogen increase throughout gestation along with those of estrone and estradiol (3,4,5). In the weeks preceding parturition, concentrations of estriol dramatically increase and continue to rise until birth (6). Estriol's roles include preparing uterine tissues for contraction and possibly signaling parturition in higher primates and humans (3,4,7,8,9,10). A rise in estriol, which can be monitored in saliva, has been shown to precede parturition, regardless of whether labor begins preterm, at term, or postterm (11,12).

Estrogens' effect on the liver has been studied extensively. The active transport of biliary components in the canaliculi is impaired by estrogen (13). The pregnant state can cause some changes in bile acid production and secretion, presumably due to the higher levels of estrogen, but also because of progesterone's effect on GI motility. This can lead to a mild subclinical cholestasis. Studies have shown conflicting evidence as to whether there is an increase in bile acid levels during pregnancy. As estrogen increases are known to induce a cholestasis, and urobilinogen levels increase in cholestasis, our hypothesis is that the increase in estrogen levels within the last week of pregnancy may slow the clearance of bile even further yielding the rise in urobilinogen levels noticed on routine dipstick.

An in depth literature review was performed in an effort to find a correlation between maternal weight loss and the onset of labor. No supporting literature validated or explained our clinical observation.

Methodology This study will be a retrospective chart review of all eligible patients who presented to labor and delivery at Oklahoma State University Medical Center between the dates of January 1, 2002 and December 31, 2006. We selected this particular time period of charts to review, because they are recent enough to be accessible, and we estimate they will yield usable data for about 200 women.

The study population will include mothers between the ages of 18 and 34 years of age with a single intrauterine pregnancy between 37 weeks and 41 weeks gestational age. (Both very young mothers and women 35 and older have increased risk of premature delivery.) The patients will have an admission diagnosis of either active labor or spontaneous rupture of membranes. Active labor is defined as uterine contractions resulting in changes either in the cervical dilatation, the effacement of the cervix and/or descent of the fetal head in the pelvis.

This study will review chart data collected from our obstetrical clinic, OSU Obstetrics and Gynecology, as well as OSU Medical Center records. We will first search the hospital's records for patients admitted with the diagnosis of active labor. These charts will be examined for inclusion/exclusion criteria and entered into the study if they are eligible (as later defined). Once these charts have been obtained, we will then search their corresponding clinic chart for the defined parameters of our study.

Eligibility Criteria:

Our study population will consist of women between the ages of 18 and 34 who delivered a single, viable, term infant at OSU Medical Center between January 1, 2002 and December 31, 2006. Gestational age must be greater than 37 weeks and less than 41 weeks, as ascertained by certain last menstrual period and/or first trimester ultrasound. The chart must include a diagnosis of active labor or spontaneous rupture of membranes, and the patient must have had at least two third-trimester prenatal checkups at OSU Houston Center OB/GYN, including one during the last two weeks of gestation. We will define a term infant as 37 weeks gestation or greater (3). Our study population will consist of mainly Medicaid patients. The ethnic blend of our study population will include Caucasian, African-American, Hispanic, American Indian, and Asian women.

We will exclude women with multiple gestation, because they are at risk of preterm labor. We will also exclude anyone else who had preterm delivery. In addition, we will exclude women with a diagnosis of liver disease, including intrahepatic cholestasis and hepatitis, chronic hypertension, intraamniotic infection, preeclampsia or its variant, HELLP syndrome, cholelithiasis, inadequate prenatal care, preterm labor, or induction of labor (other than due to premature rupture of membranes).

Data Collection Only the investigators will have access to the patients' data collection sheet. Individual physicians involved in the care of a specific patient will have access to that patient's information. All individuals will be in compliance with HIPPA guidelines as set forth by the university and the medical center. Patient records will be locked in a file cabinet or kept with their regular charts in the patient records department of the OSU Houston Center OB/GYN clinic. Any information obtained from hospital labor and delivery charts will be collected by Dr. Harris. It will be directly transported from the hospital to the clinic only by her, will be kept on her person at all times en route, and will be stored in a locked folder while in transit.

The following data will be collected from the patients' hospital record.

  1. Name
  2. Birthdate
  3. Age of patient (years)
  4. Medical Record Number (MRN)
  5. Gestational age (in weeks and days)/Determined by:
  6. Initial sterile vaginal exam results (normal yes/no)
  7. Date and time of admission
  8. Admission Diagnosis
  9. Date and time of delivery
  10. Co-morbidities, pregnancy complications
  11. Delivery Mode
  12. Indication for Cesarean Section if applicable Note that it is not possible to determine the time of onset of active labor, only the time of hospital admission. We are assuming that most women who go into active, natural labor present to the hospital within 12-18 hours. The day of hospital admission, then, serves as a rough, best estimate for onset of natural, active labor.

The following data will be collected from the patients' clinic record.

  1. Patient's Name
  2. Birthdate
  3. Age
  4. MRN (megawest number)
  5. Date of delivery (from hospital record)
  6. Date of first clinic visit
  7. Number of clinic visits
  8. Weight on first clinic visit
  9. Total pregnancy weight gain
  10. Date of last clinic visit
  11. Weight at that visit
  12. Urine dipstick result at that visit
  13. Sterile vaginal exam (SVE) (dilation, effacement, station) at that visit
  14. Date of Visit prior to last clinic visit
  15. Weight at that visit
  16. Urine dipstick result at that visit
  17. SVE at that visit
  18. Pregnancy Complications

Note that after 36 weeks gestation, prenatal visits are scheduled weekly at OSU Clinics. Therefore, unless the patient is not compliant with routine visits, natural labor for a term pregnancy will take place no longer than seven days from last clinic visit. No other data will be collected from any patient charts.

Analysis:

Data will be analyzed using PC SAS Version 9.1 (SAS Institute, Cary, NC). The two components of the study will be analyzed separately. The weight loss leg of the study will utilize an independent t-test in an effort to determine the relationship of weight loss (yes/no) to time to delivery. For the urobilinogen component of the study, we will utilize correlation techniques to assess the relationship of time to delivery and urobilinogen level. Significance will be determined at the 0.05 level.

Confidentiality:

All records and lab results will be maintained at Oklahoma State University Medical Center, department of medical records and laboratory storage on the hospital's Meditech system. All of the documents linking patient names to these numbers and charts will be destroyed after data collection is complete.

Keywords
Weight loss, urobilinogen
Medical subject headings
Weight Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00826605
Study groupRoleWhat they receive
Urobilinogen increaseIncrease in urobilinogen increase on routine dipstick test at prenatal appointment after 37 weeks gestation
Weight Loss at TermWeight loss since previous prenatal appointment after 37 weeks gestation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Increase in urobilinogen on routine urine dipstick at prenatal appointment, term pregnancy

    Measured: none--chart review

Secondary outcomes (1)
  1. Maternal weight loss at term before giving birth

    Measured: none--chart review

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jan 2009 (estimated)
  2. Study startJan 2009
  3. Primary completionJul 2009
  4. Study completionOct 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00826605
Sponsor's protocol ID
200802
Status last verified
Jan 2010
First submitted
20 Jan 2009
Last updated
28 Jan 2010
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Increase in Urobilinogen in Urine Prior to Delivery and Weight Loss After 37 Weeks Gestation Prior to Delivery, run by Oklahoma State University Center for Health Sciences at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jan 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Increase in urobilinogen on routine urine dipstick at prenatal appointment, term pregnancy (time frame: none--chart review). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2010.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in